- KR₩237bn
- KR₩297bn
- KR₩3bn
Annual income statement for Genexine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | ARS/A | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 18,543 | 36,828 | 16,139 | 4,427 | 2,933 |
| Cost of Revenue | |||||
| Gross Profit | 11,677 | 31,806 | 11,363 | 387 | -1,241 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6,002 | 57,023 | 50,604 | 46,823 | 39,876 |
| Operating Profit | 12,541 | -20,195 | -34,465 | -42,397 | -36,943 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 27,536 | -48,876 | -56,831 | -66,860 | -65,412 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 27,536 | -48,876 | -56,831 | -66,860 | -63,706 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 27,570 | -48,042 | -55,974 | -66,874 | -63,706 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 21,304 | -48,042 | -55,974 | -66,874 | -63,706 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -894 | -1,360 | -2,665 | -1,624 | -1,513 |
| Dividends per Share |